<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269319</url>
  </required_header>
  <id_info>
    <org_study_id>MRX-I-03</org_study_id>
    <nct_id>NCT02269319</nct_id>
  </id_info>
  <brief_title>MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection</brief_title>
  <acronym>ABSSSI</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of MRX-I Versus Linezolid in Adult Subjects With Acute Bacterial Skin and Skin Structure Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicuRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MicuRx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid
      in the treatment of adult patients with acute bacterial skin and skin structure infections
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients at the early assessment visit with a 20% reduction in ABSSSI lesion size compared to baseline</measure>
    <time_frame>48-72 hours</time_frame>
    <description>Did not receive a systemic antibacterial agent with activity against gram-positive organisms
Did not die of any cause up to EA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Screening though Day 28</time_frame>
    <description>Changes in vital signs, ECG parameters and laboratory data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of MITT patients at the early assessment visit with a 20% reduction in ABSSSI lesion size compared to baseline</measure>
    <time_frame>48-72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients at EOT with a 80% reduction in ABSSSI lesion size compared to baseline</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with resolution or near resolution of most baseline ABSSSI symptoms and signs absence or near absence of systemic signs of infection at Post Trial Assessment</measure>
    <time_frame>7-14 days after the End of Therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a microbiological outcome of eradication or presumed eradication at Post Trial Assessment</measure>
    <time_frame>7-14 days after the End of Therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK of MRX-I Tablets</measure>
    <time_frame>Day 3 and Day 7</time_frame>
    <description>â€¢ Influence of baseline subject characteristics on blood levels of MRX-I</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>MRX-I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRX-I tablets 800 mg given twice a day for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linezolid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Linezolid 600 mg given twice a day for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRX-I</intervention_name>
    <description>Oral MRX-I 800mg given twice a day for 10 days</description>
    <arm_group_label>MRX-I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>Oral linezolid 600mg given twice a day for 10 days</description>
    <arm_group_label>Linezolid</arm_group_label>
    <other_name>Zyvox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with systemic signs of infection diagnosed with acute bacterial skin and skin
             structure infection (ABSSSI)

          -  Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections

        Exclusion Criteria:

          -  Uncomplicated skin infections

          -  Severe sepsis or septic shock

          -  ABSSSI solely due to gram-negative pathogens

          -  Prior systemic antibiotics within 96 hours of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABSSSI</keyword>
  <keyword>MRX-I</keyword>
  <keyword>Acute Bacterial Skin and Skin Structure Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

